Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma - Mazzaferro, Vincenzo; El-Rayes, Bassel F.; Droz dit Busset, Michele; Cotsoglou, Christian; Harris, William P.; Damjanov, Nevena; Masi, Gianluca; Rimassa, Lorenza; Personeni, Nicola; Braiteh, Fadi; Zagonel, Vittorina; Papadopoulos, Kyriakos P.; et al. (British journal of cancer, 2019)
Keywords: 631/67/1059/602; 692/4028/67/1504/1329/1326; Adult; Aged; Aged, 80 and over; Alkaloids - administration & dosage; Alkaloids - adverse effects; Asthenia; Biomedical and Life Sciences; Biomedicine; Cancer Research; Chemotherapy; Cholangiocarcinoma; Cholangiocarcinoma - drug therapy; Cholangiocarcinoma - genetics; Cholangiocarcinoma - pathology; Clinical Trials as Topic; Disease control; Drug Resistance; Enzyme inhibitors; Epidemiology; Fatigue; Female; Fibroblast growth factor receptor 2; Fibroblast growth factor receptors; Gene fusion; Humans; Hyperphosphatemia; Kinases; Male; Middle Aged; Molecular Medicine; Mutation; Next-generation sequencing; Oncogene Proteins, Fusion - drug effects; Oncogene Proteins, Fusion - genetics; Oncology; Patients; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Receptor, Fibroblast Growth Factor, Type 2 - genetics; Toxicity; Tumors